Form D · Pharmaceuticals
Havah Therapeutics, Inc.
Longmont, CO · CIK 0002025011
Offering snapshot reported May 30, 2024 · SEC filing
- Reported sold
- $507K Offering amount: $507K
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 17, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 30, 2024 | Initial | $507,434 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-514623
Source: Form D, filed May 30, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Matthew Brewer | Director, Executive |
| Ronald Martell | Director |
| Jim Weiss | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2112 Andrew Alden St
Longmont, CO, 80504
Longmont, CO, 80504